Spots Global Cancer Trial Database for A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
Official Title: A Phase Ib Study of Tolerance and Safety of a Recombinant Anti-PD-1 Monoclonal Antibody HX008 in Patients With Advanced Solid Tumors
Study ID: NCT04825392
Conditions
Interventions
Study Description
Brief Summary: HX008 is a humanized monoclonal antibody targeting PD-1 on the T cell surface, restores T cell activity, thus enhancing immune response, and has the potential to treat various types of tumors. In this study, the tolerance and safety of HX008 in patients with advanced solid tumors will be evaluated.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hunan Cancer Hospital, Changsha, , China
Hunan Cancer Hospital, Changsha, , China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
